Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-53038 in Advanced or Metastatic Solid Tumors
NCT06585488Phase 1Terminated
- Sponsor
- BeOne Medicines
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of BGB-53038 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 4 more (5 arms), sponsored by BeOne Medicines. Primary endpoints: Adverse Events at 2 years, Maximum Tolerated Dose at 2 years and 4 more. Started Dec 2024; status: terminated.
02
Drugs
BGB-53038
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06585488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06585488.